Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
Microsoft Plans $50 Billion AI Investment to Accelerate Growth in the Global South 
BlueScope Steel Forecasts Stronger Second-Half Earnings, Shares Rise Above Rejected Buyout Offer 
Santos Wins Court Case Over Net Zero and Sustainability Claims 
Federal Court Fines Mobil Oil Australia A$16 Million for Misleading Fuel Claims 
India AI Impact Summit 2026: Global Tech CEOs Join World Leaders in New Delhi 
Macquarie-Led Consortium to Acquire Qube Holdings in A$11.7 Billion Deal 
Stock Market Movers: NVIDIA and Meta Expand AI Partnership as Cadence Surges on Earnings 
Luxury Stocks Face Volatility as AI Market Swings and Hedge Fund Bets Rattle LVMH and Kering 
Treasury Wine Estates Profit Falls 46% as China and U.S. Inventory Reset Weighs on Earnings 
Ireland’s Data Protection Commission Launches GDPR Investigation Into X’s AI Chatbot Grok 
Mitsui Kinzoku Stock Surges to Record High After Profit Forecast Upgrade and Dividend Increase 
Goldman Sachs Reportedly Drops Diversity Criteria From Board Candidate Evaluations 
Medical Groups Sue FTC Over Gender-Affirming Care Investigations Amid Trump Policy Dispute 
Anthropic’s Claude AI Reportedly Used in U.S. Operation to Capture Nicolas Maduro 
Hedge Funds Cut Nvidia, Amazon and Microsoft Stakes as AI Valuation Concerns Rise 
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
NEW YORK, April 30, 2018 -- Maxim Group LLC, a leading full service investment banking, securities and wealth management firm today announced the expansion of its Equity Research platform with the appointment of Caroline Palomeque as a Senior Vice President and Senior Biotechnology Analyst.
Prior to joining Maxim Group, Ms. Palomeque was a Senior Research Analyst covering the Biotechnology sector at Noble Life Science Partners and WallachBeth Capital. She has equity research experience at Oppenheimer, JMP Securities, Goldman Sachs, and Natexis Bleichroeder. Ms. Palomeque has conducted research at Mount Sinai School of Medicine in molecular epidemiology and neurotoxins. She also coauthored several scientific papers which were peer-reviewed academic journals. “I am pleased to add someone with Caroline’s experience background to our Healthcare Platform. Healthcare is a core vertical at Maxim Group and Biotechnology is an important component,” said Anthony V. Vendetti, Executive Managing Director and Head of Equity Research at Maxim Group.
Ms. Palomeque holds an M.B.A. in Finance from Fordham University Graduate School of Business and a B.S. in Neuroscience from the University of Massachusetts Amherst.
About Maxim Group LLC
Maxim Group LLC is a full-service investment banking, securities and wealth management firm headquartered in New York. The Firm provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed-income and derivatives sales & trading, equity research and prime brokerage services to a diverse range of corporate clients, institutional investors and high net worth individuals. Maxim Group is a registered broker-dealer with the U.S. Securities and Exchange Commission (SEC) and the Municipal Securities Rulemaking Board (MSRB), and is a member of the following: Financial Industry Regulatory Authority (FINRA); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and NYSE Arca, Inc. To learn more about Maxim Group, visit www.maximgrp.com.
For further information please contact:
John J. Garrity
Chief Marketing Officer
212.895.3624
[email protected]
